par Lam-Hoai, Xuan-Lan 
;Steels, Emmanuelle ;Willaert, F.;Richert, Bertrand
Référence Revue médicale de Bruxelles, 39, 5, page (429-436)
Publication Publié, 2018-10-01
;Steels, Emmanuelle ;Willaert, F.;Richert, Bertrand Référence Revue médicale de Bruxelles, 39, 5, page (429-436)
Publication Publié, 2018-10-01
Article révisé par les pairs
| Résumé : | Psoriasis is a chronic, inflammatory disease associated with many comorbidities. The development of new biologic agents has revolutionized the therapeutic options in psoriasis. These biotherapies are essential in the management of moderate-to-severe psoriasis. However, they are associated with contraindications and side effects that require a good knowledge of the molecules and use of prescription. |
